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Hence, reports published in 1998 of an asso-
ciation between serum phosphate levels and 
mortality based on data from the United 
States Renal Data System 1 resulted in an 
explosion of interest and research. Despite an 
almost complete absence of con$ rmatory 
data from interventional randomized con-
trolled trials, the link seemed to $ t intuitively 
in the minds of most clinicians, and as a 
result the quest for the  ‘ ideal phosphate 
binder ’ has accelerated in a way that would 
never have been envisaged a decade ago. 
Lanthanum carbonate is a product of this 
quest, but because previously it had been 
thought to have no medicinal applications, 
very little was known of its pharmacokinet-
ics, and reasonable concerns have been raised 
about possible deposition and mechanisms 
of elimination. Sadly, these concerns have 
been ampli$ ed by the marketing strategies of 
other phosphate binder manufacturers, so 
that the injection of some elegant science 
into the debate is both timely and welcome. 
 Bervoets  et al. 2 (this issue) demonstrate 
masterly use of advanced basic-science 
techniques to investigate and clarify a 
clinical conundrum. A combination of 
three techniques, probably not familiar to 
most nephrologists, was used to localize 
lanthanum to the lysosomes in the liver of 
rats. First lanthanum was co-mapped 
with iron with the synchrotron particle 
accelerator in Grenoble to induce X-ray 
microfluorescence; then transmission 
electron microscopy and $ nally electron 
energy-loss spectroscopy enabled identi-
$ cation and subcellular localization of 
lanthanum to the lysosomes. 
 Lysosomes are organelles generated by 
the Golgi apparatus that appear in the cyto-
plasm as bodies bounded by a single mem-
brane. ; ey can contain over 30 di3 erent 
hydrolytic enzymes, and material requiring 
digestion is $ rst deposited within them. In 
addition, they can take up antigens and 
metals, including copper and iron. ; is 
study appears to have also identi$ ed the 
liver lysosomes as the route of transport for 
lanthanum, from serum to bile and, there-
aM er, excretion via the intestine. ; e other 
particularly intriguing aspect of this study 
is the demonstration that intestinal uptake 
of lanthanum appears to be increased in 
rats with chronic kidney disease compared 
to those with normal kidney function. ; e 
difference is relatively small but leads 
the authors to speculate that it may be 
related to increased intestinal  ‘ permeability, ’ 
which has previously been demonstrated 
in uremic rats. ; e mechanism by which 
intestinal permeability may be increased 
is not known, but Bervoets  et al. 2 focus on 
the possibility that it is related to an in5 am-
matory state. However, it is also known that 
both zinc de$ ciency 3 and hyperprolactine-
mia, 4 neither of which is uncommon in 
patients on dialysis, modulate intestinal 
permeability, and there may also be other 
mechanisms at play. 
 Intestinal transporters of dietary  ‘ essen-
tial metals, ’ including zinc transporters, 
divalent metal transporter 1 (DMT1), fer-
roportin, and calcium transporter 1, have 
been identi$ ed in mammals. ; ese trans-
porters are upregulated or downregulated 
according to the host ’ s essential-metal 
nutritional status. For example, iron 
depletion is thought to upregulate mRNA 
encoding functional DMT1, an apical iron 
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 Ten years ago, mineral metabolism in dialy-
sis patients was of limited interest to the 
nephrology community, perhaps because the 
e3 ect of its derangement was thought to be 
similarly limited — to the skeleton. However, 
cardiac and cerebral vascular disease is 
responsible for the majority of deaths in 
patients with chronic kidney disease, and 
deposition of phosphate and calcium can be 
seen radiologically in the blood vessels of 
many dialysis patients. We know that the 
5 – year survival of patients around the age of 
60 years and on dialysis is worse than that of 
patients with breast cancer and colon cancer, 
and only marginally better than that of 
patients with ovarian cancer ( Table 1 ). 
see original article on page 389
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 Mineral metabolism in chronic kidney disease is attracting intense 
interest and unprecedented levels of research. The pharmaceutical 
industry has responded by developing various new agents. Bervoets 
 et al. report the use of an unusual combination of basic-science 
techniques to increase understanding of the kinetics of one such agent —
 lanthanum carbonate — in the gastrointestinal tract and liver. However, 
do we need to answer more fundamental clinical questions before we 
can definitively identify the role of similar new and expensive drugs? 
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transporter, in the small intestine in order 
to acquire more iron. 5 ; is upregulation 
has been shown to increase cadmium 
uptake from the gastrointestinal tract, 6 
and it is possible that lanthanum absorp-
tion could be in5 uenced in a similar fash-
ion depending on the make-up of the 
animal ’ s diet. However, it is not clear at 
present which if any of these transporters 
can carry lanthanum, or whether the 
di3 erential e3 ect of kidney failure on lan-
thanum absorption seen in rats applies to 
humans at all. Certainly there are impor-
tant species differences in intestinal 
absorption of various drugs, demonstrated 
in rats compared with monkeys and com-
pared with humans. 7 
 ; e techniques used by Bervoets  et al. 2 
are of course not new to science, but their 
application to the pharmacokinetics of a 
relatively new pharmaceutical, in the set-
ting of kidney disease, is both inspiring 
and thought-provoking. It demonstrates 
an informative collaboration of clinical 
medicine, university-based basic scien-
tists, and the pharmaceutical industry. 
Recently clinicians have questioned the 
in5 uence of industry on the medical pro-
fession, 8 particularly in the production of 
clinical guidelines, and with good reason. 
However, although at times it appears that 
we cannot live with each other, it is also 
clear that we cannot live without each 
other. We will always need major invest-
ment of pharmaceutical research to pro-
duce answers to clinical problems. 
; erefore it is incumbent on clinicians, 
scientists, and industry to build on such 
examples of meticulous research for the 
good of all, and in particular to improve 
the lot of the patient with chronic kidney 
disease on dialysis. 
 Lanthanum carbonate has now been 
administered to a small, self-selected 
group of dialysis patients for up to 6 years 9 
without evidence of toxicity that would 
suggest accumulation. Placed in the con-
text of a 5-year survival of older patients 
on dialysis of only around 46 % , these 
6-year data are reassuring, and the clearer 
understanding of lanthanum metabolism 
a3 orded by this latest publication adds to 
that confidence. However, it would be 
wrong to be complacent, and continued 
clinical vigilance coupled with an ongoing 
program of research is essential. At the 
same time, I am frequently troubled by the 
nagging feeling that the nephrology com-
munity collectively, myself included, is 
unwittingly behaving rather like the 
emperor Nero — fiddling while Rome 
burns! Of course it is exciting to see new 
pharmaceutical agents becoming availa-
ble, to aid us in our struggle to achieve 
the targets laid out so authoritatively 
in numerous guidelines. And to further 
our understanding of their metabolism is 
fascinating. Yet their development costs, 
and their $ nal cost to the health system, are 
massive, and our guidelines that provide 
these agents with a  raison d ’ ê tre are mostly 
opinion based, with no rigorous science 
underpinning them in the way that science 
underpins this work of Bervoets  et al. 2 
 Guidelines were $ rst introduced in the 
area of anemia management, and thou-
sands of patients have reaped the rewards 
of rapid achievement of a physiologically 
reasonable hemoglobin and hematocrit. 
The benefit to the patient in terms of 
quality of life alone is clearly visible to doc-
tor and patient alike. Do we understand 
phosphate, parathyroid hormone, and 
vitamin D pathophysiology equally well to 
say the same of bone and mineral disorder 
guidelines? Unfortunately, we do not. 
 Where are the randomized controlled 
trials to demonstrate that reducing serum 
phosphate in a dialysis patient will 
improve survival? I suspect it will, but 
currently we are still reliant on hypotheses 
generated by observational, historical-
cohort studies, which from a scienti$ c 
point of view we know to be seriously 
5 awed. I believe we have been seduced by 
our guidelines, which we have elevated to 
the status of dogma — to be neither ques-
tioned nor subjected to randomized con-
trolled trials! Look again at  Table 1 . For 
the sake of our patients, should we not 
abandon the industry-led game of  ‘ my 
phosphate binder / vitamin D analogue is 
better than yours, ’ and apply some science 
to the question of whether lowering serum 
phosphate from 7.0  mg / dl to 4.0  mg / dl 
could improve 5-year survival to 50 % or 
better? Do we have the courage to rand-
omize patients to such levels within a trial, 
or are we so certain that spending increas-
ing amounts of money and research 
expertise on expensive pharmaceuti-
cals is the correct use of resources? Our 
colleagues in hematology deal with several 
relatively rare tumors and realized many 
years ago that the only way to improve 
outcomes was to try to enter all patients 
into national and international multi-
center trials. In this way they have made 
steady progress, while nephrology has 
drifted, mesmerized by the belief that 
achievement of opinion-based biochemi-
cal targets is an end in itself. Hopefully, 
KDIGO (Kidney Disease: Improving Glo-
bal Outcomes) is about to debunk some 
of this narcissism, with a refreshing dose 
of honesty about our current level of 
knowledge. 
 Undertaking long-term outcome stud-
ies in chronic kidney disease patients is 
di4  cult and expensive, but there are some 
good examples for us to follow — the 
HEMO trial, SHARP-2, ADEMEX, 
DCOR, and others. ; e results of these 
interventional studies have been mostly 
negative, but probably none of them 
would have been possible without indus-
try sponsorship, and I suspect Bervoets 
 et al. might not have been able to a3 ord 
access to the synchrotron, transmission 
electron microscopy, and electron energy-
loss spectroscopy without industry spon-
sorship either. Clearly, we need transparent 
collaboration with our colleagues in 
industry, and they need us to prescribe 
their pharmaceuticals, but should they be 
sponsoring guidelines based on  “ low, very 
low, and missing evidence ” ? 10 
 Table 1 |  Approximate UK 5-year 
survival 5 gures for patients aged about 
60 years, with HIV infection, common 
cancers, and dialysis (without 
transplantation) 
 HIV+HAART, >95% 
 Testicular cancer, 95% 
 Breast cancer, 85% 
 Bladder cancer, 75% 
 Kidney transplant, 75% 
 Rectal cancer, 62% 
 Cervical cancer, 60% 
 Colonic cancer, 54% 
 Dialysis, 46% (10-year survival   <  15%) 
 Ovarian cancer, 44% 
 Stomach cancer, 20% 
 Lung cancer, 10% 
 HAART, highly active antiretroviral therapy. 
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 So we need to return to the hard work 
of scienti$ c endeavor and cooperation, 
exemplified by the article by Bervoets 
 et al. , 2 and try to chart a route to better 
survival for our patients. But the clinicians 
and patients must decide the destination; 
then the scientists can advise on the best 
route, and industry must oil the wheels. 
We need everyone to be on board, but at 
present I fear the wrong people are in the 
driver ’ s seat! 
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